March 17, 2020
Video
David Polsky, MD, PhD, discusses methods to identify circulating tumor DNA in patients with melanoma.
July 26, 2019
Video
David Polsky, MD, PhD, discusses the findings from a liquid biopsy analysis of the COMBI-d trial, which is a phase III trial investigating the combination of dabrafenib and trametinib or dabrafenib alone in patients with BRAF V600E/K–mutant melanoma. Investigators found an association between the presence of baseline circulating tumor DNA (ctDNA) and a poor prognosis with the treatment of BRAF inhibitors.